Haematological malignancies implications during the times of the COVID‑19 pandemic (Review)
Article 2021 en
Authors
EP
Eleni Papakonstantinou
KD
Konstantina Dragoumani
ΑE
Αspasia Efthimiadou
Abstract
1 min read
The COVID‑19 pandemic has complicated current healthcare services for cancer patients. Patients with haematological malignancies specifically seem vulnerable to SARS‑CoV‑2 infection due to their immunosuppressed status. The COVID‑19 pandemic influences every step of the assessment and treatment of a haematological malignancy. Clinicians must adhere to strict policies to not spread the virus to their patients while they must also adjust their workflow for maximum productivity. These difficulties accentuate the ever‑present need to improve the healthcare services for cancer patients. This improvement is needed not only to combat the problems that arose from the COVID‑19 pandemic but also to establish a framework for the management of patients with haematological malignancies in potential future pandemics.
Yaseen M. Arabi, Élie Azoulay, Hasan M. Al‐Dorzi, Jason Phua, Jorge I. Salluh, Alexandra Binnie, Carol Hodgson, Derek C. Angus, Maurizio Cecconi, Bin Du, Rob Fowler, Charles D. Gomersall, Peter Horby, Nicole P. Juffermans, Jozef Kesecioğlu, Ruth Kleinpell, F.S. Machado, Greg S. Martin, Geert Meyfroidt, Andrew Rhodes, Kathy Rowan, Jean‐François Timsit, Jean Louis Vincent, Giuseppe Citerio
Narayanaswamy Venketasubramanian, Craig S. Anderson, Hakan Ay, Selma Aybek, Waleed Brinjikji, Gabriel R. de Freitas, Óscar H. Del Brutto, Klaus Faßbender, Miki Fujimura, Larry B. Goldstein, Roman L. Haberl, Graeme J. Hankey, Wolf-Dieter Heiss, Isabel Lestro Henriques, Carlos S. Kase, Jong S. Kim, Masatoshi Koga, Yoshihiro Kokubo, Satoshi Kuroda, Kiwon Lee, Tsong-Hai Lee, David S. Liebeskind, Professor Gregory Lip, Stephen Meairs,
Discussion(0)
No comments yet. Be the first to comment.